Hexaminolevulinate
(Redirected from Cysview)
 | This article may have been created or edited in return for undisclosed payments, a violation of Wikipedia's terms of use. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. (June 2019) |
 | This article needs more reliable medical references for verification or relies too heavily on primary sources. (April 2023) |  |
 | |
| Clinical data | |
|---|---|
| Trade names | Cysview, Hexvix |
| License data | |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
Hexaminolevulinate, sold under the brand name Cysview among others, is an imaging agent that lights up under blue light during a blue light cystoscopy. It is used to help detect non-muscle invasive bladder cancer (NMIBC), in particular papillary tumors and carcinoma in situ (CIS).
It made by Photocure ASA, a Norwegian pharmaceutical company.
Hexaminolevulinate is a structural analogue to 5-aminolevulinic acid (a precursor to the porphyrin ring of heme), and is internalized and processed into the photoactive protoporphyrin IX at a high rate by tumor cells. After exposure to 360-450 nm light, the porphyrin will fluoresce red.[1]
References
[edit]- ^ "Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
- ^ "Cysview- hexaminolevulinate hydrochloride kit". DailyMed. 15 November 2022. Retrieved 10 April 2023.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |